Shenzhen New Industries Biomedical Engineering (300832) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached ¥1.24 billion, up 3.28% year-over-year; YTD revenue was ¥3.43 billion, up 0.39% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥434 million, down 9.72% year-over-year; YTD net profit was ¥1.20 billion, down 12.92% year-over-year.

• Domestic main business revenue declined 10.95% YTD, while overseas main business revenue grew 21.07% YTD.

• High-end equipment sales, especially MAGLUMI X8 and X10, showed stable growth; SATLARS T8 automation line achieved 158 global installations YTD.

Financial highlights

• Q3 operating cash flow was ¥1.06 billion, up 11.08% year-over-year.

• Basic and diluted EPS for Q3 were ¥0.5520, down 9.73% year-over-year; YTD EPS was ¥1.5334, down 12.92%.

• Gross margin and operating income details not explicitly stated, but profit margins declined.

• Total assets at Q3-end were ¥9.58 billion, down 0.44% from year-end 2024.

• Shareholders’ equity increased 1.96% to ¥8.74 billion.

Outlook and guidance

• Overseas reagent business revenue grew 37.23% YTD, supporting future international expansion.

• Company aims to meet full-year automation line installation targets, leveraging new product launches.